Amerigen's generic Cuprimine gets FDA OK
Amerigen Pharmaceuticals has received the Food and Drug Administration’s approval for penicillamine capsules in 250 mg dosage strength.
The product is the first approval for a generic of Bausch Health’s Cuprimine.
Penicillamine capsules are indicated in the treatment of Wilson's disease, cystinuria, and in patients with severe, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy.
"We are delighted to launch this first generic of penicillamine capsules. This is Amerigen's ninth U.S. product launch and the fourth time we have brought a first generic to market, with important savings for the American healthcare system," John Lowry, Amerigen's president and CEO, said.
The product is the first approval for a generic of Bausch Health’s Cuprimine.
Penicillamine capsules are indicated in the treatment of Wilson's disease, cystinuria, and in patients with severe, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy.
"We are delighted to launch this first generic of penicillamine capsules. This is Amerigen's ninth U.S. product launch and the fourth time we have brought a first generic to market, with important savings for the American healthcare system," John Lowry, Amerigen's president and CEO, said.